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Abstract
Currently approved combination regimens available for the treatment of metastatic tumors, such as breast cancer,
have been shown to increase response rates, often at the cost of a substantial increase in toxicity. An ideal com-
bination strategy may consist of agents with different mechanisms of action leading to complementary antitumor
activities and safety profiles. In the present study, we investigated the effects of the epigenetic modulator apicidin
in combination with the cytotoxic agent docetaxel in tumor breast cell lines characterized by different grades of
invasiveness. We report that combined treatment of apicidin and docetaxel, at low toxicity doses, stimulates in
metastatic breast cancer cells the expression of CTCF-like protein and other cancer antigens, thus potentially favoring
an antitumor immune response. In addition, apicidin and docetaxel co-treatment specifically stimulates apoptosis,
characterized by an increased Bax/Bcl-2 ratio and caspase-8 activation. Importantly, following combined exposure
to these agents, metastatic cells were also found to induce signals of immunogenic apoptosis such as cell surface
expression of calreticulin and release of considerable amounts of high-mobility group box 1 protein, thus potentially
promoting the translation of induced cell death into antitumor immune response. Altogether, our results indicate
that the combined use of apicidin and docetaxel, at a low toxicity profile, may represent a potential innovative strategy
able to activate complementary antitumor pathways in metastatic breast cancer cells, associated with a potential
control of metastatic growth and possible induction of antitumor immunity.
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Introduction
Combining therapeutics with strengthened antitumor activity is a
major challenge in the clinical management of patients with cancer.
The highest therapeutic value of these strategies relies both on en-
suring tumor cell death and increasing the immunologic recognition
of poorly immunogenic cancer cells [1].
Metastatic breast cancer is a heterogeneous disease characterized by
deregulation of multiple cellular pathways governing tumor cell prolif-
eration, survival, cell cycle control, apoptosis, angiogenesis, and meta-
static invasiveness [2]. The choice of treatment for this cancer is based
on patient-specific factors, such as the expression of estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2
[3]. Up to now, chemotherapy is the first-line treatment option for
the highly metastatic endocrine-resistant cancer types, often associated
with substantial toxicity. Advances in therapeutic strategies against
breast cancer suggest that combination of selected regimens may pro-
duce synergistic efficacy with a manageable toxicity profile. An ideal
combination regimen would consist of agents with different mecha-
nisms of action leading to complementary antitumor activities and
no cross resistance [4].
The taxane docetaxel is well known for its efficacy in patients with
breast cancer but also for its adverse toxic effects due to the dosage
[5]. Histone deacetylase inhibitors (HDACi) are a class of anticancer
agents with a potential role in the treatment of breast cancer [6].
Among HDACi, apicidin suppresses the growth of human breast
cancer cells by modulating cell cycle and inducing apoptosis [7–9].
Apicidin in combination with doxorubicin significantly increases apop-
tosis and caspase activation in hepatocellular carcinoma leading to sig-
nificantly amplified antitumor effects compared to the treatment with
either apicidin or doxorubicin alone [10]. Interestingly, apicidin was
selected as a suitable starting point for developing a second generation
of HDACi with better potency [11]. In the light of this, it is of great
interest to investigate the antitumor activity as well as the adverse
effects exerted by a combination regimen with apicidin and docetaxel
for treating metastatic breast cancer.
One of the potential immunomodulatory effects of a combined
therapy based on the use of apicidin and docetaxel is the activation
of cancer testis (CT) genes, the most immunogenic cancer antigens
known to date [12]. Among these, CTCF-like protein (CTCFL), also
called Brother of the Regulator of Imprinted Sites, has been found to
be deregulated in various types of tumor and to control the expres-
sion of the well-known tumor-associated antigens NY-ESO-1 and
MAGE-A1 [13–15]. CTCFL is overexpressed by several breast cancer
cell lines and by about 70% of human breast tumor tissues [16]. Of
interest, it has also been detected in leukocytes of patients with breast
cancer as an early marker of tumorigenesis [17]. Notably, CTCFL
tested in the setting of an anticancer vaccine for the treatment of the
highly metastatic and poorly immunogenic 4T1 mammary carcinoma
elicited a strong immune response able to delay the appearance of
tumors and to prolong significantly survival of the mice [18].
Overcoming apoptosis resistance of cancer cells remains one of
the major objectives of new potential strategies of treatment for
breast cancer, including combination therapies [19]. BCL-2 family
members include important regulators of apoptosis whose modulated
expression in breast cancer cells is tightly associated with the response
to therapeutic treatments as well as to disease outcome [20]. There-
fore, regulators such as the antiapoptotic Bcl-2 and the proapoptotic
Bax remain major targets of anticancer therapies [21]. Recently,
the concept of immunogenic apoptosis has been associated with a
chemotherapeutic agent–specific cancer cell death modality able to
potentiate anticancer immunity similarly to an anticancer vaccine
[22]. Immunogenic apoptosis occurs through activation of diverse
cellular signals, including the translocation of calreticulin (CRT)
from inside the cell to the surface as well as the release of high-
mobility group box 1 protein (HMGB1). CRT is supposed to act
not only as an important “eat me” signal for professional phagocytes
but also as a central anticancer immunity mediator, thus playing an
active role in inducing antitumor immune response [23]. Moreover,
another important inflammatory signal related to immunogenic apop-
tosis is given by HMGB1, a chromatin-associated nuclear protein
subjected to a large number of post-transcriptional modifications regu-
lating its trafficking from the nucleus to the cytoplasm and its further
release. This protein is released in the extracellular compartment by
apoptotic cells during the late phase of cell death and acts as a pro-
inflammatory signal able to trigger a potent immune response [24].
This event may also occur throughout the activation of dendritic cells
(DCs) that increase antigen processing and presentation, thus deter-
mining efficient cytotoxic T-cell activation [25].
In the present study, we investigated the antitumor efficacy of a
new therapeutic regimen based on the combination of the epigenetic
compound apicidin and the cytotoxic agent docetaxel in three differ-
ent breast cancer cell lines characterized by diverse grade of tumori-
genicity and metastatic behavior. We evaluated the molecular events
potentially leading to the effectiveness of this therapeutic option
in metastatic breast cancer cell lines and found the occurrence of
direct as well as immune-mediated antitumor signals. Co-treatment
of apicidin and docetaxel, at a low toxicity profile, induced high
expression of CTCFL in highly metastatic breast cancer cells.
Moreover, these cells exposed to apicidin and docetaxel combined
treatment exhibited increased apoptosis associated to Bcl-2 down-
modulation. Importantly, cell death induced by this combined
treatment showed signals of immunogenic apoptosis such as CRT
exposure on cell surface and HMGB1 release. On the whole, these
events may ensure at once induction of immunomodulatory events
and tumor cell death, possibly enhancing the antitumor response
toward poorly immunogenic breast cancer cells.
Materials and Methods
Cell Culture
The following three breast cell lines with different tumorigenicity/
invasiveness ability were used: highly metastatic MDA-MB-435
cells, invasively growing MDA-MB-231 cells, and poorly invasive
MCF-7 cells [26]. Cell cultures were maintained at 37°C, with
5% CO2 under fully humidified conditions in RPMI-1640 (Lonza,
Verviers, Belgium) supplemented with 10% FBS (EuroClone, West
York, United Kingdom), 2 mM glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin (Lonza).
Drug Treatment Regimens
Apicidin was purchased from Sigma Inc. (St Louis, MO). Docetaxel
was kindly provided by G. Pascale Institute (Naples, Italy).
Cell Viability Assay
CellTiter 96 AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI) was used to determine cytotoxicity effects
after treatment with drugs. Absorbance at 450 nm was determined
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on Opsys MR spectrophotometer (DYNEX Technologies, Denkendorf,
Germany), using Windows Revelation QuickLink software. Cells were
plated at a density of 5 × 103 cell/well in 96-well plates, and then treated
with various concentrations of apicidin and docetaxel for 24, 48, and
72 hours. At the end of treatment period, 20 μl of 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) reagent were added to each well. The plates were then incubated
for 2 hours at 37°C in the dark. Each experimental condition was
performed in triplicate and repeated at least twice. All values were
normalized with respect to the viability of untreated cells.
RNA Isolation, Reverse Transcription, and Quantitative
Real-time Polymerase Chain Reaction Analysis
Total RNA was isolated from cultured cells with RNeasy Mini Kit
(Qiagen, Chatsworth, CA), according to the manufacturer’s in-
structions, quantified using Thermo Scientific NanoDrop ND-100
(Wilmington,DE), and then converted to cDNAusing randomprimers
and ThermoScript reverse transcriptase (Invitrogen, Carlsbad, CA).
Quantitative real-time polymerase chain reaction (qPCR) analysis was
performed using the Applied Biosystems 7500HT Real-Time PCR
System. CTCFL expression was determined by using the follow-
ing primers/probe sequences: 5′-CCCATTGTGCCACCATCA-3′
(sense), 5′-AGCATGCAAGTTGCGCATAT-3′ (antisense), and
6FAM-ACGGAAAAGCGACCTAC-MGB (CTCFL probe) [15].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers/probe
mixture was determined by Predeveloped Assay (Applied Biosystems,
Foster City, CA). NY-ESO-1 and MAGE-A1 expression was analyzed
by using the following primer sequences: 5′-CCCCACCGCTTCCC-
GTG-3′ (NY-ESO-1 forward), 5′-CTGGCCACTCGTGCTGGGA-3′
(NY-ESO-1 reverse), 5′-CGGCCGAAGGAACCTGACCCAG-3′
(MAGE-A1 forward), and 5′-GCTGGAACCCTCACTGGGTTG-
CC-3′ (MAGE-A1 reverse). PCR reactions were prepared using 2.0 μl
of cDNA diluted in SensiMix SYBR Kit (Bioline, London, United
Kingdom). Amounts of mRNA transcripts were expressed in rela-
tive copy numbers normalized to the housekeeping gene GAPDH
(comparative C t method).
Detection of Cell Death
Apoptosis and necrosis were assessed by flow cytometry following
fluorescein isothiocyanate (FITC)–conjugated Annexin V (Annexin
V–FITC) and propidium iodide (PI) staining (ApoAlert; Clontech
Laboratories, Palo Alto, CA). Briefly, after a 24-hour drug treat-
ment, cells were harvested by trypsinization, pooled, washed twice
with PBS, and incubated with Annexin V–FITC and PI, accord-
ing to the manufacturer’s instructions. Cells were analyzed using
FACSCalibur (Becton Dickinson, Franklin Lakes, NY). Data analy-
sis was performed by WINMDI software and expressed as percentage
of positive cells.
DC Generation and Drug Treatments
Peripheral blood mononuclear cells (PBMCs) were purified from
heparinized blood obtained from healthy donors on a density gradient
(Lymphoprep; Nycomed Pharma AS, Oslo, Norway). Monocytes were
positively sorted using anti–CD14-labeled magnetic beads (MACS;
Miltenyi, Bergisch Gladbach, Germany), according to the manufac-
turer’s instructions. Freshly isolated monocytes were resuspended in
complete medium with 10% FBS containing granulocyte-macrophage
colony-stimulating factor (GM-CSF; 50 ng/ml) and interleukin-4
(IL-4; 1000 U/ml) at 2 × 106 cell/ml in 6-well plates for 5 days. On
day 5, DCs were collected, washed, and cultured in the presence or
absence of the drugs for 24 hours. Immunofluorescent staining was
performed to detect human leukocyte antigens (HLA-DR), CD83,
CD80, CD86, and CD40 molecules (BD Biosciences).
Western Blot Analysis
CTCFL expression was assessed by lysing cells with a high salt
lysis buffer containing 500 nM Tris-HCl (pH 7.5), 300 nM NaCl,
1% NP40, 5 mM EDTA, and a protease inhibitor mixture (Roche
Diagnostics, Mannheim, Germany). Equal amounts of total proteins
were boiled in sample buffer and separated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). Following
immunoblot analysis with a polyclonal rabbit antibody (Ab) against
CTCFL (Abcam, Cambridge, United Kingdom), immunoreactive
bands were visualized by using HRP-conjugated secondary Ab and the
ECL system (Amersham Biosciences, Buckingham, United Kingdom).
To examine major histocompatibility complex class I (MHC I), Bcl-2,
Bax, and caspase-8 expression, we extracted cells with a modified RIPA
lysis buffer [250 mM Tris-HCl (pH 8), 137 mM NaCl, 2 mM EDTA
(pH 8), 0.5% NP40, 10% glycerol, and protease inhibitor mixture
(Roche Diagnostics)]. Equal amounts of total proteins were boiled
in sample buffer and separated by SDS-PAGE. Following alternative
immunoblot analysis with Abs [mouse anti-human HLA-ABC, mouse
anti-human Bcl-2 (Dako, Glostrup, Denmark); rabbit anti-human Bax
(Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-human
caspase-8 (Cell Signaling Technology, Danvers, MA)], immunoreactive
bands were visualized by using the specific HRP-conjugated secondary
Ab and the ECL system (Amersham Biosciences). HMGB1 expression
was analyzed in cell supernatants. Briefly, equal amounts of each sam-
ple normalized by cell number were separated by SDS-PAGE, and
immunoblot analysis was performed with a rabbit polyclonal Ab to
HMGB1 (Abcam). The optical density of the bands [integrated area
in arbitrary units (AU)] was measured by using the National Institutes
of Health Image J software (rsb.info.nih.gov/ij).
Confocal Laser Scanning Microscopy Analysis
For confocal laser scanning microscopy (CLSM) analysis, cancer cell
lines were seeded in 24-well cluster plates on cover glasses (diameter:
12 mm; 2 × 105 cells/well). After a 48-hour drug treatment, cells were
fixed by 3% paraformaldehyde (30 minutes at 4°C), permeabilized by
0.5% Triton X-100 (10 minutes at room temperature; Sigma-Aldrich),
and then stained at 37°C with rabbit polyclonal anti-CTCFL or
anti-HMGB1 Abs (Abcam) followed by Alexa Fluor 488–conjugated
secondary Abs (Molecular Probes, Eugene, OR). The specificity of
the polyclonal anti-CTCFL Ab was tested by staining cells with Ab
preincubated with the immunogenic peptide, as negative control.
Afterward, the cover glasses were extensively washed with PBS and
then mounted on the microscope slide with Vectashield antifade
mounting medium (Vector Laboratories, Burlingame, CA) containing
4,6-diaminidino-2-phenylindole (DAPI). CLSM observations were
performed with a Leica TCS SP-2 AOBS apparatus, using a 63×/
1.40 NA oil objective and 405- to 488-nm excitation spectral laser
lines appropriately tuned by acousto-optical tunable filter. Image acqui-
sition and processing were carried out using the Leica Confocal Soft-
ware 2.6 rel 1537 (Leica, Lasertechnik, Heidelberg, Germany) and
Adobe Photoshop CS2 1.4.10 software programs (Adobe Systems,
San Jose, CA). Signals from different fluorescent probes were taken
in sequential scan settings. Different fields of view were analyzed on
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the microscope for each labeling condition, and representative results
are shown.
Membrane CRT Expression
Immunofluorescent staining was used to detect CRT exposure in
breast cancer cell lines treated with drugs. Briefly, 2 × 105 cells were
plated in 6-well plates and, 24 hours after treatment, were collected
with EDTA, washed twice with PBS, and incubated for 30 minutes
with a goat CRT-specific polyclonal Ab diluted 1:10 (Santa Cruz
Biotechnology). After a 10-minute incubation with cold blocking
buffer (human AB serum), cells were washed and incubated with the
FITC-conjugated polyclonal secondary Ab diluted 1:500 (30 minutes).
Samples were analyzed by FACSCalibur (Becton Dickinson) and
WINMDI software. Isotype-matched IgG Abs were used as control.
Statistical Analysis
Data were represented as means ± SD of determinations from either
three or more independent experiments. Statistical analysis was carried
out using unpaired Student’s t test. Values were considered as significant
when the probability was below the 5% confidence level (P ≤ .05).
Results
Combined Treatment with Apicidin and Docetaxel Strongly
Modulates CTCFL in Highly Metastatic Breast Cancer Cells
and Exerts Immunomodulatory Effects
Apicidin has been shown to suppress the growth of human breast
cancer cells, whereas docetaxel is one of the most effective chemo-
therapeutic agent with antiproliferative effect on breast cells [7,27].
Figure 1. CTCFL is differently expressed in MDA-MB-435, MDA-MB-231, and MCF-7 cell lines. (A) qPCR analysis of CTCFL transcripts in
selected human breast cell lines. Levels of CTCFL mRNA were calculated using absolute normalization of C t and normalized to GAPDH
levels (ΔC t). Experiments were performed in triplicate, and each value represents mean ± SD of three independent experiments, *P <
.05. (B) One representative Western blot analysis of three of total cell lysates showing the total content of CTCFL in the different breast
cancer cell lines. Actin was used as quantitative loading control. In the lower panel, the blot was incubated with CTCFL-specific peptide
blocking CTCFL Ab, as negative control. (C) CLSM analysis of fixed and permeabilized cells stained for intracellular CTCFL (gray). Offset
and gain values of the photomultiplier channel were regulated with respect to the setup selected for MDA-MB-435 cell analysis to make
fluorescence intensity comparable across experiments on different samples. Nuclei were stained with DAPI (blue). The specificity of the
polyclonal Ab was assessed by staining cells with a combination of anti-CTCFL Ab and the immunogenic peptide. A representative example
of four independently repeated experiments is shown. Scale bars, 20 μm.
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The potentially immunogenic CTCFL is absent in normal breast
cells, whereas it is present at variable levels in all breast cancer cell
lines, both in the nucleus and in the cytoplasm [16]. Thus, we in-
vestigated whether the co-treatment with apicidin and docetaxel
stimulated the immunogenicity of breast cancer cells by inducing
high expression of CTCFL at low toxicity doses. To this end, we first
examined CTCFL basal expression in three breast cancer–derived
cell lines with different grades of tumorigenicity, i.e., the highly
metastatic MDA-MB-435, the invasively growing MDA-MB-231,
and the poorly invasive MCF-7 cells. CTCFL mRNA and protein,
assayed by qPCR, Western blot, and CLSM analyses, were detected
at high levels in MDA-MB-435 cells but barely in MDA-MB-231
and MCF-7 cells (Figure 1). No staining was detected in the presence
of CTCFL-specific peptide blocking CTCFL Ab in all tested breast
cancer cell lines (Figure 1, B and C ). In agreement with earlier re-
ports, these data confirmed that CTCFL is present at variable levels in
breast cancer cell lines with different grades of tumorigenicity [16,28].
Then, to choose the optimal dosage of drugs with a low toxicity pro-
file able to induce CTCFL, we tested apicidin and docetaxel to cause
cytotoxic effects on breast cancer cell lines in vitro by using MTS
assay. Thus, cells were treated with rising doses of drugs for 24, 48,
and 72 hours. We found that both agents inhibited cell proliferation
in a time- and dose-dependent manner (Figure W1). Rising doses of
apicidin determined growth inhibition and cell death at the same ex-
tent in all breast cancer cell lines, whereas docetaxel exhibited a stronger
antiproliferative effect against MDA-MB-435 and MDA-MB-231 cells
Figure 2. Combined treatment of apicidin and docetaxel induces CTCFL expression in metastatic breast cancer cells. (A) CTCFL mRNA
was measured by qPCR in all breast cancer cell lines after 24-hour treatments, and the relative levels were calculated using comparative
C t method (ΔΔC t) and normalized to GAPDH levels. Data represent the mean relative fold changes ± SD of three independent experi-
ments, *P < .05. (B) CTCFL Western blot analysis of cell lysates untreated or after 48-hour treatment with medium and high doses of
A and D, alone or in combination. (C) Intracellular CTCFL expression monitored by CLSM on cells exposed for 48 hours to different doses
of A and D, alone or in combination. Cells, fixed and permeabilized, were stained with polyclonal anti-CTCFL Ab (gray). Nuclei are shown
in blue (DAPI). A representative example of three independent experiments is reported. Scale bar, 20 μm. Ctr, untreated; A, apicidin;
D, docetaxel, A + D, apicidin and docetaxel combined treatment.
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rather than MCF-7 cells. These results defined the nontoxic doses of
apicidin and docetaxel, closest to the IC20 values for all tested cell lines
at 48-hour treatment, as the highest nontoxic concentrations to be
used in our experiments. This allowed us to preserve cell viability while
studying the mechanism of action of these drugs. Thus, the experi-
ments were performed by using 100, 500, and 1000 nM apicidin
and 0.1, 1, and 2.5 nM docetaxel, namely, as low, medium, and high
doses, respectively. We then assessed the modulation of CTCFL in
all tested breast cancer cell lines following co-treatment with apicidin
and docetaxel. Combined administration of medium doses, and to a
lesser extent of high doses, of these drugs resulted in a marked increase
of CTCFL expression, both at mRNA and protein levels, in the highly
metastatic MDA-MB-435 cells compared to single drug treatments
(Figure 2, A and B). In MDA-MB-231 cells, CTCFL modulation
occurred under high-dose apicidin treatment (Figure 2, A and B). By
contrast, the same treatments, at all tested concentrations, did not
induce any CTCFL modulation in MCF-7 cells (Figure 2, A and B).
We further investigated the intracellular localization of CTCFL after
co-treatment with apicidin and docetaxel by CLSM analysis. We found
that, although apicidin alone induced a moderate increase of CTCFL
expression in MDA-MB-435 cells, combined treatment with medium
doses of apicidin and docetaxel for 48 hours caused a clear-cut up-
regulation of this protein, which accumulated in defined nuclear areas
faintly stained with DAPI, indicating euchromatin regions. Consistent
with qPCR and Western blot analyses, the expression and distribution
of CTCFL did not significantly change in MDA-MB-231 and MCF-7
cells in any experimental conditions (Figure 2C ). Of interest, combined
low doses of drugs determined a significant CTCFL overexpression
only in MDA-MB-435 cells, although to a lesser extent than that
occurring at medium-dose co-treatment (Figure W2, A and B). To
Figure 3. Combination of apicidin and docetaxel upregulates persistent CTCFL expression and other CTs in MDA-MB-435 cells.
(A) CLSM analysis of fixed and permeabilized MDA-MB-435 cells treated with A and D, alone or in combination, for 72 hours; Ab detection
of intracellular CTCFL (gray) is shown; nuclei are stained by DAPI in blue. A representative example of three independently repeated
experiments is reported. Scale bars, 20 μm. (B) NY-ESO-1 and MAGE-A1 mRNA expression was evaluated by qPCR in the three cell lines
after single and combined treatments with medium and high doses of A and D. Expression levels were calculated using the comparative
C t method (ΔΔC t) and normalized to GAPDH expression. A representative example of three independently repeated experiments is shown,
*P < .05.
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specifically evaluate the persistence of CTCFL overexpression, we per-
formed CLSM analysis in MDA-MB-435 cells subjected to long-term
drug co-treatment. We found that after a 72-hour exposure to low
doses of combined drugs the expression of CTCFL returned at basal
levels, whereas medium and high doses of drugs prolonged the per-
sistence of CTCFL expression, thus suggesting its transient control
induced by the combined treatment with apicidin and docetaxel in a
dose- and time-dependent manner (Figure 3A). Given the selectively
nuclear accumulation of CTCFL following combined treatment with
apicidin and docetaxel at certain doses and its persistence overtime,
we sought to assess whether the modulation of MAGE-A1 and NY-
ESO-1, reported to be CTCFL targets, occurred in treated MDA-
MB-435 cells. qPCR analysis revealed significant up-modulation
of NY-ESO-1 and, to a lesser extent, MAGE-A1 after a 48-hour
treatment of cells with high doses of combined drugs (Figure 3B). Con-
versely, MDA-MB-231 andMCF-7 cells did not display any significant
regulation of both genes under the same experimental conditions (data
not shown). Of interest, we also investigated the expression of MHC I
on cancer cells as sign of an efficient presentation of tumor antigens
to CD8+ T lymphocytes [29], and we found that combined high
doses of apicidin and docetaxel, over the single treatments, increased
the expression of this molecule significantly in the highly metastatic
MDA-MB-435 cells (Figure W3).
Apicidin and Docetaxel Combined Treatment Induces
Activation of DCs
In the light of the strong modulation induced by combined apicidin
and docetaxel treatment on CT expression, we next assessed whether
apicidin and docetaxel co-treatment could affect the immunostimula-
tory functions of DCs, major antigen-presenting cells whose activity
is known to be potentiated in effective antitumor immune responses
generated by drug treatments [30]. Therefore, monocyte-derived DCs
were treated with the two drugs, alone or in combination, for 24 hours
and analyzed for the expression of maturation and activation markers by
fluorescence-activated cell sorting (FACS) analysis. Upon treatment
with medium and high doses of apicidin alone, we found a significant
increased expression of the maturation and activation molecules MHC
II, CD86, and CD83 (Figure 4). Of interest, the combination treat-
ment of apicidin and docetaxel significantly enhanced CD83 expression
(Figure 4). By contrast, CD40 or CD80 levels did not change in the
same experimental conditions (data not shown). These results demon-
strate that apicidin and docetaxel co-treatment is able to elicit DC
maturation and activation, thus favoring their functional activity in the
tumor microenvironment.
Apicidin and Docetaxel Co-treatment Promotes Apoptosis
Selectively in Metastatic Breast Cancer Cells
Overcoming resistance to apoptosis remains a major objective of
therapeutic treatments in breast cancer [20]. Therefore, we sought to
investigate whether apicidin and docetaxel combined treatment ex-
erted an additive effect on inducing apoptosis in metastatic breast
cancer cells. First, we treated MDA-MB-435, MDA-MB-231, and
MCF-7 cells with medium and high doses of both drugs, alone or
combined, for 24 hours and measured apoptosis by Annexin V and
PI staining. As shown in Figure 5A, high doses of combined drugs, with
respect to the single agents, induced significant apoptosis, revealed by
the increased number of Annexin V+/PI− and Annexin V+/PI+ cells, in
both MDA-MB-435 and MDA-MB-231 cells. Moreover, this latter
cell line showed an increased apoptosis following co-treatment with
medium doses of apicidin and docetaxel (Figure 5A). By contrast, no
significant additive apoptotic effects were observed in MCF-7 cells
at any dose of drugs in combination (Figure 5A). To further dissect
the potential proapoptotic effects of apicidin and docetaxel combined
treatment, we assessed whether these drugs determined the modula-
tion of two pivotal members of the BCL-2 family, namely, Bcl-2
and Bax, and the activation of caspase-8. We found that both high
and medium doses of combined drug treatment of MDA-MB-435 cells
for 48 hours significantly reduced the levels of the antiapoptotic pro-
tein Bcl-2, whereas the expression of the proapoptotic protein Bax
did not change in the same experimental conditions (Figure 5B).
These simultaneous events determined a marked enhancement of
Bax/Bcl-2 ratio specifically in high drug dose–treated MDA-MB-
435 cells (Figure 5B). Of interest, although MDA-MB-231 cells re-
sulted susceptible to apoptosis induced by medium and high combined
Figure 4. Apicidin and docetaxel co-treatment modulates activation and maturation markers on DCs. FACS analysis of MHC II, CD83,
and CD86 expression on monocyte-derived DCs cultured with A and D, alone or in combination, for 24 hours. The percentage of positive
cells is shown for each panel. Similar data were obtained in three independent experiments using three different donors.
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doses of apicidin and docetaxel, they did modulate neither Bcl-2
expression nor Bax/Bcl-2 ratio, similarly to what was observed in
MCF-7 cells (Figure 5B). Concurrently, a significant activation of
caspase-8 was also found in MDA-MB-435 cells upon co-treatment
with medium and high doses of apicidin and docetaxel with respect
to any agent alone, whereas this event was minimal in both MDA-
MB-231 and MCF-7 cells under the same experimental conditions
(Figure 5C ).
Taken together, these data demonstrate that the combination of
high doses, more than medium ones, of apicidin and docetaxel com-
pared to single-agent treatment was effective in stimulating apoptosis
signals in the highly metastatic MDA-MB-435 cells and, to a lesser
extent, in the invasively growing MDA-MB-231 cells, whereas the
nonmetastatic MCF-7 cells were completely refractory to these effects.
Apicidin and Docetaxel in Combination Induce Signals of
Immunogenic Apoptosis and HMGB1 Release in Metastatic
Breast Cancer Cells
Given the immunomodulatory activities and the proapoptotic effects
of combined apicidin and docetaxel in the highly metastatic MDA-
MB-435 cells, we sought to investigate whether this coupling was
effective also in inducing immunogenic apoptosis, recently emerged
as chemotherapeutic agent–specific immunogenic cancer cell death
modality able to induce “anticancer vaccine effect” [23]. Thus, we
assessed two typical signals distinguishing immunogenic apoptosis
such as early cell surface exposure of CRT and HMGB1 extracellular
release. Of interest, we found that high doses of combined apicidin
and docetaxel, over the single treatments, significantly increased the
levels of CRT on cell membrane in highly metastatic MDA-MB-435
Figure 5. Apicidin and docetaxel combined treatment stimulates proapoptotic signals in metastatic breast cancer cells. (A) FACS anal-
ysis of apoptosis (Annexin V+PI− and Annexin V+PI+) and necrosis (Annexin V−PI+) in MDA-MB-435, MDA-MB-231, and MCF-7 cell lines
treated with medium or high doses of A, D, or A + D for 24 hours. All data are expressed as mean ± SD of five independent experi-
ments. Statistical significance was performed by comparison of each treated cell group with Ctr cells, *P< .05. (B) Bcl-2 and Bax protein
detection by Western blot analysis of lysates from 48-hour treated cells with medium and high doses of A and D, alone or in combi-
nation. Intensities of both Bcl-2 and Bax bands were measured and values normalized to actin are expressed as AU at the bottom of
each panel; Bax/Bcl-2 ratio expression was evaluated on the normalized values and shown in the bottom panel. One representative
experiment of three is shown. (C) Pro–caspase-8 and active caspase-8 protein expression of 48-hour treated cells with medium and
high doses of A and D, alone or in combination. One experiment of two is shown.
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cells after a 24-hour treatment, whereas the invasively growing MDA-
MB-231 cells exhibited high levels of CRT on cell surface follow-
ing treatment with both medium and high doses of combined drugs
(Figure 6A). By contrast and in agreement with the apoptosis data,
no significant induction of CRT was observed on the surface of
MCF-7 cells. Next, the assessment of the expression and localization
of HMGB1, deemed as potential immune-response inducer and
secreted during late stages of apoptosis, provided the most striking
signal of immunogenic apoptosis induced by apicidin and docetaxel
combined treatment with respect to any agent alone in metastatic breast
cancer cells. As shown in Figure 6B, a clear-cut accumulation of
HMGB1 in cytoplasm occurred specifically in MDA-MB-435 cells and,
to a lesser extent, in MDA-MB-231 cells, upon 48-hour co-treatment
with medium or high doses of combined apicidin and docetaxel, as de-
termined by CLSM analysis. Of note, this phenomenon was not detect-
able in the nonmetastatic MCF-7 cells under the same experimental
conditions (Figure 6B). Consistent with this, the Western blot analysis
of supernatants of tumor cell cultures strikingly confirmed a synergistic
Figure 6. Apicidin and docetaxel combined treatment induces CRT exposure on cell surface and HMGB1 release in metastatic breast
cancer cells. (A) FACS analysis of CRT expression was evaluated as mean fluorescence intensity (MFI) on live breast cancer cell lines
(PI− gate). Data are represented as mean value ± SD of three independent experiments. P values were calculated with respect to Ctr,
*P < .05. (B) CLSM detection of HMGB1 by a polyclonal rabbit anti-human Ab in MDA-MB-435, MBA-MB-231, andMCF-7 cells exposed
for 48 hours to medium and high doses of A and D, alone or in combination (gray, arrows). Nuclei stained with DAPI are blue. Three
independent experiments were performed on each cell line. Scale bar, 20 μm. (C) HMGB1 extracellular release assayed byWestern blot
analysis of supernatants from breast cancer cell lines treated for 48 hours with medium and high doses of A and D, alone or in combi-
nation. Intensities of bands were measured and values expressed as AU are given at the bottom of each panel; four independent experi-
ments were performed.
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or additive effect of the combined treatment with apicidin and
docetaxel, respectively, at medium and high doses, in inducing secre-
tion of HMGB1 by MDA-MB-435 cells. Of interest, this phenome-
non was much less evident inMDA-MB-231 cells at the medium doses
of drug combination (Figure 6C ). By contrast, detectable levels of
HMGB1 were found in the supernatants of nonmetastatic MCF-7
cells only following treatment with high doses of single or combined
drugs (Figure 6C ). Notably, the marked synergistic activity of apicidin
and docetaxel in inducing increased expression of HMGB1 was not
observed upon low doses of combined drug treatment in all breast
cancer cell lines (Figure W4). These data demonstrate that apicidin
and docetaxel, at a low toxicity profile, act synergistically in inducing
signals of immunogenic apoptosis such as cell surface CRT expres-
sion and release of extracellular HMGB1 in metastatic breast tumor
cells, thus potentially translating induced cell death into an antitumor
immune response.
Discussion
New combination therapies for cancer are highly expected to obtain
enhanced efficacy and improved selectively along with low toxicity. In-
deed, the major objective of drug combination is to keep under control
multiple or alternative cellular pathways that result deregulated in can-
cer cells avoiding drug resistance and subsequent clinical relapse [31].
Enhancing immunogenicity of cancer cells and simultaneously ensur-
ing tumor cell death may potentially improve the response to therapeu-
tic treatment by activation of direct and immune-mediated antitumor
responses. On this basis, numerous HDACi in conjunction with other
treatments such as chemotherapy, biologic therapy, or radiation therapy
are currently under investigation in clinical trials [32,33]. A phase II
study of the HDACi vorinostat combined with tamoxifen for the treat-
ment of patients with hormone therapy–resistant breast cancer has
shown that this therapeutic combination treatment exhibits encourag-
ing activity in reversing hormone resistance [34]. Similarly, other
studies suggest that manipulating protein acetylation by HDACi in
combination with hormonal therapies is a promising approach in breast
cancer [35]. Very recently, two reports have highlighted that HDACi
may potentiate anticancer effect of docetaxel in hormone refractory
prostate cancer cells through modulation of Bcl-2 family proteins
[36,37]. In this study, we report that the combination of low doses
of the HDACi apicidin and the taxane docetaxel, acting through com-
plementary molecular mechanisms, provides additive anticancer effects
over single-agent treatment with low toxicity profiles in metastatic
breast cancer cells. Our results show that, in the highly metastatic
MDA-MB-435 cells, the combination of these agents, with respect
to the single treatments, causes the simultaneous activation of diverse
cellular events, namely, CTCFL overexpression and enhanced immu-
nogenic apoptosis with cell surface CRT expression and extracellular
HMGB1 release, potentially leading to increased immunogenicity of
tumor cells. Of interest, all these effects occurred in a limited manner
in the less aggressive MDA-MB-231 cells and were not detected in the
poorly invasive MCF-7 cells, thus suggesting a selective effect of these
drugs on metastatic breast cancer cells.
Previous reports highlighted that CTCFL is detected at weak to
moderate levels in breast cancer cell lines and the frequency of its acti-
vation is higher in metastatic tumors than primary lesions [16,38,39].
By contrast, CTCFL mRNA was not observed in eight patients with
breast cancer, suggesting, in this case, a link between high methylation
and absence of CTCFL expression [28]. Here, the highly invasive
MDA-MB-435 cells were found to express high levels of CTCFL
compared to invasively growing MDA-MB-231 cells and the non-
metastatic MCF-7 cells. Interestingly, combined treatment with
apicidin and docetaxel compared to each agent alone determined a
strong induction of CTCFL specifically in metastatic cancer cells.
CTCFL expression is methylation dependent and it may also be af-
fected by modification of histones [13,40]. Here, for the first time,
we report that apicidin, a potent emerging HDACi, controls CTCFL
expression and this activity is sustained by docetaxel. CTCFL has been
reported to activate the expression of several CT genes, among which
many members of the MAGE-A family and NY-ESO-1 [15,41] are
already in cancer vaccine trials [42]. CTCFL represents an essential
mediator of 5-aza-2′-deoxycytidine for MAGE-A1 derepression and
may physically interact with the NY-ESO-1 promoter controlling its
expression [14,15]. Therefore, a model has been suggested wherein
CTCFL is a potential global regulator of other well-known CTs cur-
rently tested in cancer immunotherapy [43]. However, the correlation
between CTCFL and other CT expression was not found in all tested
human cells and tissues, implying a quite complex and conflicting
CTCFL control on other CT genes in diverse cancer cells [40]. One
suggested possibility is that CTCFL acts in concert with other protein
partners such as Sp-1 forming a transcriptional regulatory complex that
activates NY-ESO-1 in lung cancer cells [13]. Alternatively, it is con-
ceivable that a particular isoform of CTCFL is necessary for the regu-
lation of a defined CT so much that activation of other CT genes
occurs only when a general expression of CTCFL is induced by a strong
stimulus [38]. In this study, treatment of MDA-MB-435 cells with
combined high doses of apicidin and docetaxel with respect to single-
agent condition represents a stimulus strong enough to induce a
persistent expression of CTCFL, which may then potentially favor up-
modulation of both the tumor antigens NY-ESO-1 and MAGE-A1.
Notably, MDA-MB-231 and MCF-7 cells did not display any signif-
icant regulation of all these genes. Given that spontaneous potent anti-
tumor immune responses can be elicited in some patients with cancer
bearing CT antigen-expressing tumors [44], our present findings indi-
cate that apicidin, and even more its combination with docetaxel, is
strongly efficacious in augmenting tumor immunogenicity of meta-
static breast cancer cells. In this respect, we also observed that combined
apicidin and docetaxel compared to single-agent treatment increase
MHC I expression on the surface of malignant breast cancer cells. It
is worth mentioning that the simultaneous increased expression of
CTs and MHC I molecules by epigenetic drugs has been reported to
enhance the ability of tumor cells, such as neuroblastoma and ovarian
cancer cells, to be recognized by antigen-reactive CD8+ T cells [45]. Of
interest, low-dose chemotherapy can elevate antigen presentation by
MHC I potentiating immune sensitization of tumors [46,47].
However, HDACi as well as taxanes may act on antigen-presenting
cells such as DCs by modulating their function [48–50]. In the
present study, apicidin was found to induce significant up-regulation
of CD86 and its combination with docetaxel was able to further
modulate the increase of the maturation surface molecule CD83 on
human monocyte-derived DCs. HDACi can modulate positively or
negatively the expression of costimulatory signals such as CD86 on
DCs depending on their maturation stage [51,52]. Here, we envisage
that the combination of apicidin and docetaxel over single-agent
treatment may favor the expression of DC costimulatory and mat-
uration molecules supporting their functional activity within the
inflammatory response.
Both apicidin and docetaxel are able to induce apoptosis in several
types of tumor cells including breast cancer cells [8,53]. In this study,
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we report that in metastatic breast cancer cells the combination of
apicidin and docetaxel compared to each agent alone induces the
activation of conventional cell death pathways as well as signals re-
lated to immunogenic apoptosis. Recently, the concept of immuno-
genic cell death, relying on the capacity of a cytotoxic compound to
trigger a cell death modality able to elicit cross priming by DCs of
tumor antigen-specific T cells thus enhancing treatment tumoricidal
activity, has emerged in some settings of chemotherapy [54,55]. This
modality of cell death is distinct by “danger” and “eat me” signals
such as CRT surface exposure and secretion of HMGB1 that deliver
stimulatory signals to the immune system [23]. Here, we report that
the highly invasive MDA-MB-435 cells treated with combined
apicidin and docetaxel with respect to single-agent treatment exhibit
a strong inhibition of the antiapoptotic Bcl-2 leading to an increase
of the Bax/Bcl-2 ratio and a significant enhancement of cell sur-
face CRT exposure. Moreover, in these same experimental condi-
tions, a proteolytic maturation of caspase-8 was observed. Of interest,
caspase-8 cleavage following endoplasmic reticulum stress seems to be
associated with CRT exposure on cell surface in the early phase of
immunogenic cell death [56]. Therefore, we envisage that apicidin
and docetaxel, combined at low cytotoxic doses, may trigger cellular
stress signals leading to both cell death and increased immunogenicity
of metastatic cells.
HMGB1 release represents the main post-apoptotic signal of im-
munogenic cell death elicited by chemotherapeutic treatments [57].
Oxidized HMGB1 increases the cytotoxicity of chemotherapeutic
agents or ionizing radiation and induces apoptosis through the
mitochondrial pathway, whereas reducible HMGB1 induces Beclin
1–dependent autophagy and promotes cancer cell resistance to
these agents [58]. Importantly, HMGB1 transmits the “injury”
signal to immune, stromal, and epithelial cells, triggering inflamma-
tion [59]. In this study, combined apicidin and docetaxel over
single-agent treatment determined a significant synergistic trans-
location of HMGB1 from nucleus into cytoplasm and subsequent
release in supernatants in metastatic breast cancer cells. Although
HMGB1 release has been typically associated with tumor progres-
sion and resistance to chemotherapy, its function linked to anti-
tumor effects of immunotherapeutic treatments is becoming evident
[60,61]. Very recently, a therapeutic approach based on the combi-
nation of oncolytic vaccinia virus and paclitaxel has been shown to
exert synergistic antitumor effects through HMGB1 release [62].
These results suggest the hypothesis that acute HMGB1 release
stimulated by the oncolytic virus, in contrast to its chronic release
typically occurring in the tumor environment, may enhance the sus-
ceptibility of tumor cells to paclitaxel through activation of cellular
signals, such as cell cycle checkpoints, sensitive to this agent [63]. In
our model, we envisage the occurrence of a similar acute release of
HMGB1 triggered by apicidin, in agreement with a previous report
showing that active release of HMGB1 is determined by decreased
HDAC activity [64].
In summary, we report that apicidin and docetaxel, at low toxicity
doses and over single-agent treatment, stimulate direct and immune-
mediated antitumor effects in metastatic breast cancer cells, suggest-
ing a rationale for using such combination in patients with advanced
metastatic disease. These findings further emphasize the urgent need
to develop novel combination therapies for treating malignant dis-
eases, including metastatic breast cancer, by useful combinations of
drugs functioning through complementary mechanisms of action
with a manageable toxicity and avoiding phenomena of cross resis-
tance. In this respect, our study shows that the combination of
apicidin and docetaxel may represent a suitable option. These drugs,
when combined, target complementary cellular pathways leading, on
the one hand, to the overexpression of immunogenic tumor antigens
and, on the other hand, to the induction of a type of cell death
resulting in the release of immunomodulatory signals potentially able
to stimulate a potent host antitumor response. In conclusion, this
report discloses the cellular bases and possible molecular mechanisms
supporting the rationale of combining HDACi with standard che-
motherapeutic agents for the treatment of patients with metastatic
breast cancer.
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Figure W1. Antiproliferative effects of medium and high doses of apicidin and docetaxel on breast cancer cell lines. Viability of drug-
treated MDA-MB-435, MDA-MB-231, and MCF-7 cells was evaluated at 24, 48, and 72 hours by MTS assay. Each value is normalized to
Ctr. Experiments were performed in triplicate and each value represents mean ± SD of three independent experiments.
Figure W2. Low doses of combined A and D induce CTCFL expression in MDA-MB-435 cells. (A) CLSM detection of CTCFL in breast
cancer cell lines exposed for 48 hours to A and D, alone or in combination, fixed, permeabilized, and stained with the polyclonal anti-
CTCFL Ab (gray). Nuclei are stained with DAPI (blue). Three independent experiments were performed on each cell line. Scale bar, 20 μm.
(B) Western blot analysis of lysates of the three cell lines treated with low doses of single or combined drugs. Actin expression represents
the internal loading Ctr. Intensities of CTCFL bands were measured and values normalized to actin are expressed as AU at the bottom of
each panel. Three independent experiments were performed.
Figure W3. Combination of apicidin and docetaxel modulates MHC I expression in the highly metastatic MDA-MB-435 cells. (A) MHC I
expression was analyzed by Western blot analysis in lysates of cells treated for 48 hours with medium and high doses of A and D, alone
or in combination. (B) Normalized quantification performed by the National Institutes of Health Image J software is shown. A representative
experiment of three is shown.
Figure W4. Low doses of combined apicidin and docetaxel do not induce extracellular release of HMGB1. CLSM analysis of HMGB1 in
cells exposed to low doses of A and D, alone or in combination, for 48 hours. Cells were fixed, permeabilized, and stained with anti-
HMGB1 Ab (gray), and nuclei were stained with DAPI (blue). Two independent experiments were performed. Scale bar, 20 μm.
